Keep up with the latest Crohn's and UC developments.
If a serious infection occurs while on an anti‑TNF drug, patients and clinicians face difficult decisions about when and whether to restart biologic therapy. This case shows one example where switching to mirikizumab...
Find updates by what you are tracking.
Automated, consistent scoring of the UCEIS could reduce subjectivity and variability in endoscopic assessment of ulcerative colitis, which matters for clinical trials, central reading, and potentially treatment decisions...
Early symptomatic improvement on filgotinib may predict longer-term gains in disease-specific quality-of-life for people with ulcerative colitis, which could help patients and clinicians set expectations during...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
Dietary changes are common among people with IBD but long-term adherence is low; understanding what patients find acceptable and what barriers they face can help clinicians design practical, culturally sensitive dietary...
Steroid dependency affects many people with ulcerative colitis and can change long-term treatment plans. This study explores clinical factors and uses an AI clustering method to visualize different risk patterns, which...
The coexistence of Peutz-Jeghers syndrome and Crohn's disease is exceptionally rare, and both conditions carry increased cancer risk. Patients, families, and clinicians need to know that there is little evidence to guide...
IBD can cause inflammation outside the gut; this report shows rare eye, facial muscle, and salivary gland involvement occurring at the time of ulcerative colitis diagnosis in a child, which could affect evaluation and...
Diagnostic delays can mean a child with Crohn's disease doesn't get timely treatment. This report shows weight loss in young patients—especially girls—can be mistakenly labeled an eating disorder, so awareness and...
Standardizing inpatient IBD care with a defined index improved measurable adherence at the authors’ center, which could reduce variability in the care patients receive during hospital stays.
Altered NAD metabolism may influence inflammation and tissue repair in IBD; understanding host and microbial contributions could open new research directions for metabolic biomarkers or therapeutic targets.
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...
Mesalazine is commonly used in UC; rare pulmonary toxicity can present with fever and progressive breathlessness. Early recognition and stopping the drug plus corticosteroids may lead to recovery and avoid invasive...
Integrated joint appointments could make it easier for children with IBD and their families to get coordinated care for symptoms, nutrition, and mental health in a single visit, which may improve access and reduce stigma...
Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
PTG and psychological wellbeing matter to many people with IBD. This study indicates that addressing stigma and promoting healthy lifestyle behaviours could be linked with better psychological outcomes, making these...
Many people with UC try dietary changes to manage symptoms. This randomized pilot trial directly compared two popular diets and did not find a clear difference in symptom improvement, but high dropout limits confidence.
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
Many people with IBD still experience active disease, poor quality of life, work impairment, and depression even while on advanced therapies — highlighting gaps in how we measure and manage treatment success. Who this...
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
People with IBD often take biologics and may need or want implant-based breast surgery.
This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...
The analysis suggests genetic liability to IBD, particularly Crohn’s disease, may raise the risk of IgA vasculitis. This is relevant for understanding overlapping immune mechanisms and possible shared pathways between...
Nanotechnology is being heavily explored as a way to improve drug targeting, control release, and reduce systemic toxicity in IBD — topics that could shape future treatment options and research priorities.
Mood disorders commonly co-occur with chronic somatic diseases, including IBD; understanding shared mechanisms may explain worse outcomes and suggest multidisciplinary care needs.
Understanding which patients are at higher risk for serious complications after IBD surgery can help patients and clinicians weigh risks, plan preoperative optimization, and guide research into preventive strategies.
Cure8 found this source from legacy.com, but the page could not be read reliably yet. It is tagged for Community and awareness. Open the original article for the full details.
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...
Lung inflammation can occur in children with IBD but is uncommon and may be hard to spot because symptoms can be vague or absent. Early recognition matters because imaging, bronchoscopy, and sometimes biopsy help...
The study explores a novel method to reduce gut oxidative stress — a contributor to IBD inflammation — by using an engineered probiotic to edit NOX2, which could point toward new therapeutic strategies if translated to...
Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.
VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...
Cure8 found this source from waff.com, but the page could not be read reliably yet. It is tagged for Community and awareness. Open the original article for the full details.
Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...
This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...
Fecal incontinence is a distressing symptom that lowers quality of life and appears linked to active disease in UC. Knowing which patients are at higher risk can help clinicians focus assessment and symptom support.
If reliable, an earlier day‑3 PUCAI cutoff could help identify children with flare‑related ASUC who are unlikely to respond to IV steroids and who may benefit from earlier planning for second‑line therapy rather than...
Identifies a new molecular checkpoint (RADX versus IFI16) linking replication stress/genome instability to innate immune activation and intestinal inflammation, suggesting potential targets for future IBD treatments or...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery. The original article is from ANZ Journal of Surgery.
This article suggests a naturally derived compound (isorhamnetin) identified from TCM may reduce inflammation in experimental ulcerative colitis and points to the Nrf2–PTGS2 pathway as a possible mechanism. That could...
An infectious cause (amebic colitis) can mimic IBD on colonoscopy and imaging, even without symptoms; misdiagnosis could delay correct treatment.
Stoma creation and whether it can later be closed greatly affects daily life and planning for people with Crohn's disease.
The paper identifies microbiome-derived peptides that can directly block TLR4 signaling and reduce intestinal inflammation in mice; this reveals a new microbiome–immune mechanism that could inform future IBD treatments.
Metabolic syndrome appears common in this Tunisian IBD cohort (about one-third). MetS can affect overall health and may influence long-term outcomes for people with IBD, so awareness and cardiometabolic screening may be...
